Research graph
References from New treatment approaches for older adults with multiple myeloma. Local targets link to admitted publications; unresolved targets remain external evidence.
Future of cancer incidence in the United States: burdens upon an aging, changing nation
10.1200/jco.2008.20.8983 · 2009 · External reference
Review of 1027 patients with newly diagnosed multiple myeloma
10.4065/78.1.21 · 2003 · External reference
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome
10.1056/nejm199607113350204 · 1996 · External reference
Declining myeloma mortality rates in the United States following introduction of novel therapies
2011 · External reference
Recent major improvement in long-term survival of younger patients with multiple myeloma
10.1182/blood-2007-08-104984 · 2008 · External reference
Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data
10.1634/theoncologist.2011-0229 · 2011 · External reference
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens
10.1001/jama.1969.03160090040009 · 1969 · External reference
Thalidomide–dexamethasone compared with melphalan–prednisolone in elderly patients with multiple myeloma
10.1182/blood-2008-07-169565 · 2009 · External reference
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
10.1016/s0140-6736(06)68338-4 · 2006 · External reference
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
10.1182/blood-2008-04-149427 · 2008 · External reference
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
10.1016/s0140-6736(07)61537-2 · 2007 · External reference
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75years with newly diagnosed multiple myeloma: IFM 01/01 trial
10.1200/jco.2008.21.0948 · 2009 · External reference
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study
10.1200/jco.2009.26.1610 · 2010 · External reference
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
10.1182/blood-2009-08-237974 · 2010 · External reference
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
10.1111/j.1600-0609.2010.01524.x · 2010 · External reference
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant
10.3109/10428194.2011.584006 · 2011 · External reference
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials
10.1182/blood-2011-03-341669 · 2011 · External reference
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis
10.1038/leu.2010.313 · 2011 · External reference
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
10.1182/blood-2006-04-019778 · 2006 · External reference
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
10.1200/jco.2009.26.0638 · 2010 · External reference
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
10.1056/nejmoa0801479 · 2008 · External reference
10.1016/s1470-2045(10)70187-x
10.1016/s1470-2045(10)70187-x · 2010 · External reference
Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients
2010 · External reference
Patient-reported quality of life in elderly, newly diagnosed multiple myeloma patients treated with bortezomib-based regimens: results from the phase 3b UPFRONT study
2010 · External reference
Bortezomib–melphalan–prednisone–thalidomide followed by maintenance with bortezomib–thalidomide compared with bortezomib–melphalan–prednisone for initial treatment of multiple myeloma: a randomized controlled trial
10.1200/jco.2010.29.8216 · 2010 · External reference
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
10.1182/blood-2010-07-294983 · 2010 · External reference
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
10.1016/s1470-2045(09)70284-0 · 2010 · External reference
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network
10.1200/jco.2007.12.3463 · 2007 · External reference
A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients >=65years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens
2010 · External reference
A phase III study to determine the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients 65years with newly diagnosed multiple myeloma (NDMM)
2010 · External reference
Unresolved reference
2011 · External reference
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65years with newly diagnosed multiple myeloma
10.1182/blood-2006-03-013086 · 2006 · External reference
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation
10.1182/blood-2011-02-338665 · 2011 · External reference
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70years
10.1046/j.1365-2141.2001.02976.x · 2001 · External reference
Feasibility of autologous hematopoietic stem cell transplantation in patients aged ≥70years with multiple myeloma
10.3109/10428194.2011.606942 · 2012 · External reference
Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis
10.1002/ajh.21191 · 2008 · External reference
High-dose melphalan (200mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>65years) myeloma patients: comparison with younger patients treated on the same protocol
10.1038/sj.bmt.1705360 · 2006 · External reference
Autologous stem cell transplantation in multiple myeloma patients <60 vs >/=60years of age
10.1038/sj.bmt.1704288 · 2003 · External reference
The role of autologous transplantation in patients with multiple myeloma aged 65years and over
10.1038/sj.bmt.1702188 · 2000 · External reference
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
10.1182/blood-2004-02-0408 · 2004 · External reference
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients
10.1200/jco.2009.22.7561 · 2010 · External reference
Bortezomib, melphalan, prednisone and thalidomide followed by maintenance with bortezomib and thalidomide (VMPT-VT) for initial treatment of elderly multiple myeloma patients: updated follow-up and impact of prognostic factors
2010 · External reference
Maintenance therapy with bortezomib plus thalidomide (VT) or bortezomib plus prednisone (VP) in elderly myeloma patients included in the GEM2005MAS65 Spanish randomized trial
2011 · External reference
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
10.1182/blood-2010-09-307645 · 2011 · External reference
Lenalidomide (L) in combination with dexamethasone (D) improves survival and time to progression in elderly patients (pts) with relapsed or refractory (rel/ref) multiple myeloma (MM)
2006 · External reference
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
10.1111/j.1365-2141.2007.06585.x · 2007 · External reference
Multiple myeloma
10.1056/nejmra1011442 · 2011 · External reference
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
10.1182/blood-2011-06-358812 · 2011 · External reference
Neuropathy: mobility and quality of life
10.1002/dmrr.856 · 2008 · External reference
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
10.1016/s1470-2045(10)70068-1 · 2010 · External reference
Prevalence of peripheral neuropathy in multiple myeloma at initial diagnosis
10.3109/10428194.2011.598253 · 2011 · External reference
Neuropathy in multiple myeloma treated with thalidomide
10.1212/01.wnl.0000267271.18475.fe · 2007 · External reference
Neurological toxicity of long-term (>1yr) thalidomide therapy in patients with multiple myeloma
10.1111/j.1600-0609.2004.00382.x · 2005 · External reference
A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma
10.1111/j.1365-2141.2005.05914.x · 2006 · External reference
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy
10.1200/jco.2008.18.3087 · 2009 · External reference
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature
10.1002/cncr.22921 · 2007 · External reference
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
10.1200/jco.2005.04.7779 · 2006 · External reference
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
10.1016/s1470-2045(11)70081-x · 2011 · External reference
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma
10.1007/s00277-010-0925-1 · 2010 · External reference
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial
10.1200/jco.2010.31.6844 · 2011 · External reference
Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens
10.1016/j.clml.2011.03.006 · 2011 · External reference
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study
10.1200/jco.2007.14.9641 · 2008 · External reference
Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma
10.3816/clm.2008.n.031 · 2008 · External reference
Risk factors for postherpetic neuralgia
10.1001/archinte.1997.00440320117011 · 1997 · External reference
Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy
10.1002/cncr.24006 · 2009 · External reference
Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study
10.1200/jco.20.2.494 · 2002 · External reference
Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study
10.1200/jco.2011.34.7625 · 2011 · External reference
How I treat elderly patients with myeloma
10.1182/blood-2009-10-163329 · 2010 · External reference
